Some studies have reported that donor-derived allogeneic anti-CD19-CAR T-cell therapy can effectively eradicate B-cell malignancies in B-ALL patients relapsing after allo-HSCT (10, 11). Here, CD19 is linked to acute lymphoblastic leukemia.